DOCSLIB.ORG

Selegiline Enhances Erectile Activity Induced by Dopamine Injection in the Paraventricular Nucleus of the Hypothalamus in Anesthetized Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Selegiline Enhances Erectile Activity Induced by Dopamine Injection in the Paraventricular Nucleus of the Hypothalamus in Anesthetized Rats International Journal of Impotence Research (2002) 14, 518–522 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Selegiline enhances erectile activity induced by dopamine injection in the paraventricular nucleus of the hypothalamus in anesthetized rats J Allard1, J Bernabe1, F Derdinger1, L Alexandre1, K McKenna1,2 and F Giuliano1,3* 1PELVIPHARM Laboratories, Domaine INRA, Bures-sur-Yvette, France; 2Northwestern University Medical School, Department of Physiology and Urology, Chicago, IL, USA; and 3Groupe de Recherche en Urologie, UPRES, EA 1602, Medical University of Paris South, Le Kremlin Biceˆtre Cedex, France Apomorphine delivered in the paraventricular nucleus of the hypothalamus (PVN) induces penile erection in rats, suggesting a role of dopaminergic projection to the PVN in the control of penile erection. We assessed whether the selective inhibitor of monoamine oxidase B, selegiline, could enhance the erectile activity induced by dopamine delivery in the PVN. Intracavernous and blood pressure (ICP and BP) were monitored in anesthetized rats to quantify ICP rises (number and percentage of ICP maximum=mean BP (ICPmax=BP Â 100)) elicited by 10 mg dopamine injection in the PVN after saline or 3 mg=kg i.v. selegiline (8 rats per group). The number of ICP rises (mean Æ s.d.: 4.5 Æ 2.9 vs 1.4 Æ 1.9; P ¼ 0.017) and their ICPmax=BP Â 100 (49 Æ 8% vs 34 Æ 9%; P ¼ 0.015) were significantly greater upon dopamine injection in the PVN than upon vehicle. Compared to saline i.v., 3 mg=kg selegiline pretreatment significantly increased the number of ICP rises induced by dopamine injection in the PVN (9.4 Æ 2.6 vs 4.5 Æ 2.9; P < 0.001), without affecting their amplitude. This suggests that drugs potentiating dopaminergic responses in the central nervous system might enhance proerectile commands of supraspinal origin. International Journal of Impotence Research (2002) 14, 518–522. doi:10.1038=sj.ijir.3900934 Keywords: penile erection; monoamine oxidase; l-deprenyl; dopamine Introduction A corollary of the aforementioned statement is that indirect dopaminergic agonist might have some proerectile activities. Selegiline hydrochloride Peripheral delivery of apomorphine, a non-specific (registered as L-deprenyl) is a selective monoamine D1-like as well as D2-like dopamine receptor ago- oxidase inhibitor B (MAO B), which has been suc- nist, induces penile erections in rats by acting in the cessfully used alone or as an adjunctive treatment to paraventricular nucleus of the hypothalamus 3,4-dihydroxy-L-phenylalanine (L-DOPA, the pre- 1 (PVN). Injection of doses of apomorphine as low cursor of dopamine) in Parkinson’s disease.4 Experi- as 5 ng in the PVN can induce penile erections in mental data suggest that selegiline enhances 2 conscious rats. Conversely, penile erections dopaminergic responses in rats. For example, pre- induced by peripheral delivery of apomorphine are treatment with selegiline potentiated individual antagonized by a preceding injection of SCH23390, a neuronal responses of single striatal neuron to D1-like receptor antagonist or sulpiride, a D2-like iontophoretically applied dopamine in vivo.5 It receptor antagonist, in the PVN of anesthetized also increased contralateral rotations induced by 3 rats. This suggests that dopaminergic release intraperitoneal L-DOPA injections in rats with within the PVN play a key role in the control of unilateral lesion of the substantia nigra.6 The penile erection. mechanisms responsible for the effect of selegiline on dopaminergic responses differ in rats and humans. In rats, catabolism of dopamine is not affected by inhibition of MAO B by selegiline, pro- *Correspondence: F Giuliano, Department of Urology, CHU bably because of a high ratio of MAO A=MAO B de Biceˆtre, 78 rue du Ge´ne´ral Leclerc, 94270 Le Kremlin concentration.5,7 – 10 The enhanced dopaminergic Biceˆtre Cedex, France. E-mail: [email protected] responses are therefore not due to an increased Received 12 May 2002; revised 10 July 2002; availability of dopamine caused by a decreased accepted 23 July 2002 degradation by MAO B. The ability of selegiline to Enhancement of dopamine-induced erection by selegiline J Allard et al 519 increase dopaminergic responses in rats has been injection site at the end of the experiment. After explained by the amphetamine-like properties of sacrifice, the brain was removed and serially cut in L-methamphetamine, a major metabolite of selegi- 20 mm thick sections on a microtome. One in 5 slices line.11,12 It was also proposed that in the rat brain was mounted on gelatinized slides and dyed with selegiline could increase the level of b-phenylethyl- cresyl violet. Rats for which the tip of the injection amine, an endogenous trace amine which potenti- was outside the PVN were eliminated from the ates neuronal response to dopamine.5,13 – 15 study. Taking into account the potentiating activity of BP and ICP tracings were analyzed retrospec- selegiline on dopaminergic responses in rats, we tively using software designed in our laboratory. hypothesized that erectile responses induced by Only ICP rises with a maximal value superior to central dopamine could be enhanced by systemic the sum of the average þ 3 standard deviations of the selegiline pretreatment. We therefore assessed the ICP recorded during the 5 min before the injection of ability of selegiline delivered intravenously (i.v.) to drug or vehicle were quantified. Such ICP rises were enhance erectile responses induced by dopamine considered as erectile events. Latency was the time injections in the PVN in anesthetized rats. separating the beginning of the PVN injection from the first ICP rise. ICPmax=BP Â 100 corresponded to the percentage of the ratio: maximal value reached Materials and methods by ICP during the rise (mm=Hg)=mean BP(mm=Hg) for the duration of the ICP rise. The area under the curve of ICP rise divided by the mean BP, termed Thirty two adult male Sprague-Dawley rats (Charles- AUC=BP (s) and the sum of the AUC=BP (s) of all the River, St-Aubin-le`s-Elbeuf, France) weighing 200 – ICP rises, which represents an index of overall 250 g, were anesthetized with an intraperitoneal erectile activity, were also calculated for each rat. injection of urethane (1.2 g=kg, Sigma-Aldrich, St- All parameters were averaged per rat, except the Quentin-Fallavier, France). Their temperature was sum of AUC=BP, and then per treatment. Rats maintained at 37C using a homeothermic blanket. which did not display any ICP rise (non-responder Rats were tracheotomized to prevent aspiration of rats) during the recording were attributed the value saliva, and, when required, to perform artificial 0 for the sum of AUC=BP and number of ICP rises. ventilation. The carotid artery and jugular vein For non-responder rats, ICPmax=BP Â 100 and were catheterized with polyethylene tubings filled AUC=BP were considered as missing data for the with heparinized saline (25 IU=ml) to record the statistical analysis. mean systemic arterial blood pressure (BP) via a Data were compared using two way analysis of pressure transducer (Elcomatic 750, Glasgow, UK) variance (ANOVA) followed by post-hoc analysis and inject drugs into the bloodstream, respectively. with the Student – Newman – Keuls method when The prepuce was circumcised and the penis required. All tests were conducted using SigmaStat1 denuded of skin. The animal was placed on a software, version 2.03 (SPSS, Erkrath, Germany). stereotaxical apparatus. A heparinized saline-filled Differences were considered significant when catheter connected to a pressure transducer (Elco- P < 0.05. All results are expressed as mean Æ standard matic EM 750, UK) was inserted in the left corpus standard deviation (s.d.). cavernosum to record intracavernous pressure (ICP). Selegiline (Sigma-Aldrich) was dissolved in saline and dopamine (Sigma-Aldrich) in saline sup- Results plemented with 0.05% ascorbic acid to retard oxida- tion. Intravenous injection of selegiline (3 mg=kg) or the corresponding vehicle injection was performed In the groups injected with vehicle in the PVN, selegi- 5 min after the start of recording and 10 min prior to line i.v. injection resulted in an increase in the the PVN injection. Dopamine (10 mgin1ml) or vehi- number of rats presenting at least one ICP rise com- cle were injected into the PVN (stereotaxic coordi- pared to saline i.v. injection (7=8 vs 3=8 respectively). nates: 0.3 mm posterior to bregma; 0.4 mm lateral to All rats displayed at least one ICP rise in the groups the midline; 8.4 mm below the skull surface, with injected with 10 mg dopamine in the PVN. Original the upside of the incisor bar at the level of the recordings showings the effect of dopamine injection interaural line) over 1 – 2 min using a 1 ml Hamilton in the PVN after i.v. pretreatment with either saline or microsyringe. Eight rats were included in each of the 3mg=kg selegiline are displayed in Figure 1. 4 groups (2 groups injected with selegiline i.v. and Two way ANOVA revealed a significant effect of with either dopamine or the corresponding vehicle dopamine injection in the PVN on the mean number in the PVN, 2 groups injected with saline i.v. and and sum of AUC=BP of the ICP rises (F[1,28] ¼ 30.13 with either dopamine or the corresponding vehicle and 33.91 respectively, P < 0.001 for both), as well as in the PVN). BP and ICP were recorded for 30 min on ICPmax=BP Â 100 and latency (F[1,22] ¼ 22.94, after the injection of dopamine. Evans blue was P < 0.001 and 4.39, P ¼ 0.048, respectively).
Load more

Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification
    medRxiv preprint doi: https://doi.org/10.1101/2020.08.11.20171447; this version posted November 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease Daphna Laifenfeld, PhD1,a,†, Chen Yanover, PhD2,b,†, Michal Ozery-Flato, PhD3,†, Oded Shaham, PhD2,c, Michal Rozen-Zvi, PhD3,4,*, Nirit Lev, MD/PhD1,d,‡ , Yaara Goldschmidt, PhD2,e,‡, Iris Grossman, PhD1,f,‡ 1Formerly Teva Pharmaceuticals Research & Development, Petach Tikva, Israel; 2Formerly IBM Research – Haifa, Israel; 3IBM Research – Haifa, Israel; 4Faculty of Medicine, The HeBrew University, Jerusalem, Israel; aPresent Address: Ibex Medical Analytics, Tel Aviv, Israel; bPresent Address: KI Research Institute, Kfar Malal, Israel; cPresent Address: MeMed Dx, Haifa, Israel; dPresent Address: Meir Medical Center and Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel; ePresent Address: K Health, Tel Aviv, Israel; fPresent Address: Gross Advantage, Brookline, MA, USA; † These authors contriButed equally and share first authorship. ‡ These authors contriButed equally to this work. * Corresponding author: Michal Rosen-Zvi [email protected] Haifa University Campus, Mount Carmel Haifa, 3498825, Israel Tel: (972) 04-8296517 Keywords: Real World Data; Clinical Evidence; Parkinson’s disease; Artificial Intelligence; Causal Inference; Rasagiline; Zolpidem; Disease Modifying Therapeutics; Repurposing. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Medical Review Officer Manual
    Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs EFFECTIVE OCTOBER 1, 2010 Note: This manual applies to Federal agency drug testing programs that come under Executive Order 12564 dated September 15, 1986, section 503 of Public Law 100-71, 5 U.S.C. section 7301 note dated July 11, 1987, and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008 (effective October 1, 2010). This manual does not apply to specimens submitted for testing under U.S. Department of Transportation (DOT) Procedures for Transportation Workplace Drug and Alcohol Testing Programs (49 CFR Part 40). The current version of this manual and other information including MRO Case Studies are available on the Drug Testing page under Medical Review Officer (MRO) Resources on the SAMHSA website: http://www.workplace.samhsa.gov Previous Versions of this Manual are Obsolete 3 Table of Contents Chapter 1. The Medical Review Officer (MRO)........................................................................... 6 Chapter 2. The Federal Drug Testing Custody and Control Form ................................................ 7 Chapter 3. Urine Drug Testing ...................................................................................................... 9 A. Federal Workplace Drug Testing Overview..................................................................
    [Show full text]
  • Aphrodisiac Herbal Therapy for Erectile Dysfunction
    Original Article Aphrodisiac Herbal therapy for Erectile Dysfunction Bharti Goel1, Neelesh Kumar Maurya2* 1Research Scholar Department of Foods and Nutrition, Government Home Science College, Panjab University, Chandigarh, India. 2 Research Scholar, Department of Foods and Nutrition, Institute of Home Science, Bundelkhand University, Jhansi, Uttar Pradesh, India. Abstract Erectile dysfunction (ED) or male impotence is described as an inability to maintain penile erection primarily endothelial and neuronal dysfunction which is partly characterized by decreased production of nitric oxide (NO). Male impotence can be caused by androgen deficiency in aging men, atherosclerosis, diabetes mellitus, spinal cord injury, high level of cholesterol, hypertension, prostate surgery, prostate and heart disease, penis anatomical deformity, social and psychological conditions as unhappy marital relationship, depression, and stress. Aphrodisiac is a drink or food that arouse sexuality. It can be categorized into three groups according to their action mode as follows: increase sexual pleasure substances, increase libido substances (arousal, sexual desire), and increase sexual potency (erection effectiveness). Various extracts of medicinal plants and orally active drugs such as vardenafil, sildenafil, and tadalafil are used to increase arterial blood flow for treating (ED) in southwest Asia. Hence, this paper review focuses on medicinal plants used as aphrodisiacs for scientific validation and management of erectile dysfunction (ED). Keywords: Aphrodisiacs, herbal plants, erectile dysfunction, penile erection INTRODUCTION care providers, testosterone replacement therapy for aging men has been practiced for many years but if the patient has Erectile dysfunction (ED) is a neurovascular condition that no clinical signs of androgen deficiency then testosterone involves endothelium of the corpora cavernosal arterial blood replacement therapy will have no clinical effect [13, 14].
    [Show full text]
  • Dexmethylphenidate Hydrochloride Extended-Release Capsules These
    DEXMETHYLPHENIDATE HYDROCHLORIDE- dexmethylphenidate hydrochloride capsule, extended release Granules Pharmaceuticals Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION Dexmethylphenidate hydrochloride extended-release capsules These highlights do not include all the information needed to use DEXMETHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXMETHYLPHENIDATE HYDROCHLORIDE EXTENDED RELEASE CAPSULES. DEXMETHYLPHENIDATE HYDROCHLORIDE extended-release capsules, for oral use, CII Initial U.S. Approval: 2005 WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning. • CNS stimulants, including dexmethylphenidate hydrochloride extended-release, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence( 5.1, 9.2, 9.3). • Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy ( 5.1, 9.2). INDICATIONS AND USAGE Dexmethylphenidate hydrochloride extended-release capsules are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ( 1) DOSAGE AND ADMINISTRATION • Patients new to methylphenidate: Recommended starting dose is 5 mg once daily for pediatric patients and 10 mg once daily for adults with or without food in the morning ( 2.2) • Patients currently on methylphenidate: Dexmethylphenidate hydrochloride extended-release dosage is half the current total daily dosage of methylphenidate
    [Show full text]
  • From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J
    REVIEW The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J. David Jentsch, Ph.D., and Robert H. Roth, Ph.D. Administration of noncompetitive NMDA/glutamate effects of these drugs are discussed, especially with regard to receptor antagonists, such as phencyclidine (PCP) and differing profiles following single-dose and long-term ketamine, to humans induces a broad range of exposure. The neurochemical effects of NMDA receptor schizophrenic-like symptomatology, findings that have antagonist administration are argued to support a contributed to a hypoglutamatergic hypothesis of neurobiological hypothesis of schizophrenia, which includes schizophrenia. Moreover, a history of experimental pathophysiology within several neurotransmitter systems, investigations of the effects of these drugs in animals manifested in behavioral pathology. Future directions for suggests that NMDA receptor antagonists may model some the application of NMDA receptor antagonist models of behavioral symptoms of schizophrenia in nonhuman schizophrenia to preclinical and pathophysiological research subjects. In this review, the usefulness of PCP are offered. [Neuropsychopharmacology 20:201–225, administration as a potential animal model of schizophrenia 1999] © 1999 American College of is considered. To support the contention that NMDA Neuropsychopharmacology. Published by Elsevier receptor antagonist administration represents a viable Science Inc. model of schizophrenia, the behavioral and neurobiological KEY WORDS: Ketamine; Phencyclidine; Psychotomimetic; widely from the administration of purportedly psychot- Memory; Catecholamine; Schizophrenia; Prefrontal cortex; omimetic drugs (Snyder 1988; Javitt and Zukin 1991; Cognition; Dopamine; Glutamate Jentsch et al. 1998a), to perinatal insults (Lipska et al. Biological psychiatric research has seen the develop- 1993; El-Khodor and Boksa 1997; Moore and Grace ment of many putative animal models of schizophrenia.
    [Show full text]
  • UNJ February 03
    Man’s Search for Ultimate Sex: Viagra® Abuse Jeffrey A. Albaugh Susan Kellogg-Spadt n an age when men aspire for “extreme” perfor- mance in all aspects of their lives, sexual per- safe, but encouraged the young man to seek medical formance is no exception. As a result, the drug advice prior to further use. Curiosity about Viagra sildenafil citrate (Viagra®) is being routinely abounds with men wondering about its ability to Iused and abused by men of all ages (who have not improve the quality and rigidity of erections, been diagnosed with erectile dysfunction) to facili- decrease the refractory period after ejaculation, and tate the ultimate sexual experience. Men might use increase libido. Danner (2001) reports that Viagra is this drug to counteract or coincide with other recre- one of the “party drugs” of our times and there are ational drugs, to improve the quality and longevity reports that it is prevalent in British nightclubs and of an already adequate erection, or to shorten the restaurants under the name “poke” (Canadian normal physiologic refractory period between erec- Medical Association, 1998). Widespread Viagra use tions. Although there is no indication or document- is also reported as a trend among gay men in the ed evidence for improved erectile function in party scene (Contemporary Sexuality, 2001; Men’s healthy young men, the use of sildenafil citrate Fitness, 2002). among this population is thought to improve erec- tile longevity and rigidity by these men. Mixing Drugs Man’s search for improved sexual function In recreational use, Viagra is being mixed with would be better served by his learning about the other street drugs such as ecstasy (methylene- arousal response cycle and the type and amount of dioxymethamphetamine), uppers (amphetamines), loveplay that might lead his partner to the greatest crystal methadone, and poppers (amyl nitrate) into level of satisfaction.
    [Show full text]
  • Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates
    The Journal of Neuroscience, October 8, 2003 • 23(27):9107–9115 • 9107 Behavioral/Systems/Cognitive 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates Mahmoud M. Iravani, Michael J. Jackson, Mikko Kuoppama¨ki, Lance A. Smith, and Peter Jenner Neurodegenerative Disease Research Centre, Guy’s, King’s, and St. Thomas’ School of Biomedical Sciences, King’s College, London SE1 1UL, United Kingdom Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] was shown to prolong the action of L-3,4-dihydroxyphenylalanine (L-DOPA) while suppressing dyskinesia in a single patient with Parkinson’s disease (PD). The clinical basis of this effect of MDMA is unknown but may relate to its actions on either dopaminergic or serotoninergic systems in brain. In normal, drug-naive common marmosets, MDMA administration suppressed motor activity and exploratory behavior. In 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-treated, L-DOPA-primedcommonmarmosets,MDMAtransientlyrelievedmotordisability but over a period of 60 min worsened motor symptoms. When given in conjunction with L-DOPA, however, MDMA markedly decreased dyskinesia by reducing chorea and to a lesser extent dystonia and decreased locomotor activity to the level observed in normal animals. MDMA similarly alleviated dyskinesia induced by the selective dopamine D2/3 agonist pramipexole. The actions of MDMA appeared to be mediated through 5-HT mechanisms because its effects were fully blocked by the selective serotonin reuptake inhibitor fluvoxamine. Furthermore,theeffectofMDMAon L-DOPA-inducedmotoractivityanddyskinesiawaspartiallyinhibitedby5-HT1a/bantagonists.The ability of MDMA to inhibit dyskinesia results from its broad spectrum of action on 5-HT systems.
    [Show full text]
  • The Effects of Microdose LSD on Time Perception: a Randomised, Double-Blind, Placebo-Controlled Trial
    Psychopharmacology https://doi.org/10.1007/s00213-018-5119-x ORIGINAL INVESTIGATION The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial Steliana Yanakieva1 & Naya Polychroni1 & Neiloufar Family2 & Luke T. J. Williams2,3 & David P. Luke4 & Devin B. Terhune1,5 Received: 23 May 2018 /Accepted: 9 November 2018 # The Author(s) 2018 Abstract Rationale Previous research demonstrating that lysergic acid diethylamide (LSD) produces alterations in time perception has implications for its impact on conscious states and a range of psychological functions that necessitate precise interval timing. However, interpretation of this research is hindered by methodological limitations and an inability to dissociate direct neuro- chemical effects on interval timing from indirect effects attributable to altered states of consciousness. Methods We conducted a randomised, double-blind, placebo-controlled study contrasting oral administration of placebo with three microdoses of LSD (5, 10, and 20 μg) in older adults. Subjective drug effects were regularly recorded and interval timing was assessed using a temporal reproduction task spanning subsecond and suprasecond intervals. Results LSD conditions were not associated with any robust changes in self-report indices of perception, mentation, or concen- tration. LSD reliably produced over-reproduction of temporal intervals of 2000 ms and longer with these effects most pronounced in the 10 μg dose condition. Hierarchical regression analyses indicated that LSD-mediated over-reproduction was independent of marginal differences in self-reported drug effects across conditions. Conclusions These results suggest that microdose LSD produces temporal dilation of suprasecond intervals in the absence of subjective alterations of consciousness. Keywords Interval timing .
    [Show full text]
  • Selegiline) in Monkeys*
    Intravenous self-administration studies with /-deprenyl (selegiline) in monkeys* /-Deprenyl and its stereoisomer d-deprenyl did not maintain intravenous self-administration behavior in rhesus monkeys. In contrast, /-methamphetamine, the major metabolite of /-deprenyl, as well as the baseline drug, cocaine, maintained high rates of intravenous self-administration behavior. Treatment with /-deprenyl doses up to 1.0 mg/kg before self-administration sessions failed to alter self-administra- tion of either cocaine or /-methamphetamine. Thus /-deprenyl did not appear to have cocaine- or meth- amphetamine-like reinforcing properties in monkeys and was ineffective in altering established patterns of psychomotor-stimulant self-administration behavior. These results support clinical findings that de- spite long-term use of /-deprenyl for the treatment of Parkinson's disease by large numbers of patients, no instances of abuse have been documented. /-Deprenyl has recently been suggested as a potential med- ication for the treatment of various types of drug abuse, including cocaine abuse, but its failure to pro- duce selective effects in decreasing cocaine or methamphetamine self-administration behavior in the present experiments makes such an application seem unlikely. (CLIN PHARMACOL THER 1994;56:774-80.) Gail D. Winger, PhD,a Sevil Yasar, MD,b'd'e S. Steven Negus, PhD,a and Steven R. Goldberg, pIli/i d'e Ann Arbor, Mich., and Baltimore, Md. From the 'Department of Pharmacology, University of Michigan /-Deprenyl (selegiline) has been known for several
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]